1-ethyl-3,5-bis(thien-2-yl-methyl-ene)-piperidin-4-one | 728901-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-3,5-bis(thien-2-yl-methyl-ene)-piperidin-4-one
• 英文别名: 1-Ethyl-3,5-bis(thiophen-2-ylmethylidene)piperidin-4-one
• CAS: 728901-55-1
• 化学式: C₁₇H₁₇NOS₂
• mdl: MFCD14722821
• 分子量: 315.46
• InChiKey: BKTJHWMQZDRBMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  76.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-4-甲基噻唑 、 1-ethyl-3,5-bis(thien-2-yl-methyl-ene)-piperidin-4-one 在 溶剂黄146 作用下， 反应 20.0h， 以37%的产率得到C₂₁H₂₁N₃S₃
  参考文献：
  名称：

  Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues

  摘要：

  A novel series of thiazolo[2,3-b]quinazoline (14-23, 26 and 27), and pyrido[4,3-d]thiazolo[3,2-a] pyrimidine (34-43, 45 and 46) analogues were designed and synthesized. The obtained compounds were evaluated for their in-vitro antitumor activity at the National Cancer Institute (NCI) 60 cell lines panel assay. Compounds 22, 38, 40 and 41 showed remarkable broad-spectrum antitumor activity. Compounds 22 and 38 are almost nine fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.5, >100, >100; and 2.4, 9.1, 36.2 mu M, respectively; while 40 and 41 are almost seven fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.9, 12.4, 46.6 and 3.0, 16.3, 54.0 mu M, respectively. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.023
• 作为产物：
  描述：

  2-噻吩甲醛 、 N-乙基-4-哌啶酮 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以89%的产率得到1-ethyl-3,5-bis(thien-2-yl-methyl-ene)-piperidin-4-one
  参考文献：
  名称：

  Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues

  摘要：

  A novel series of thiazolo[2,3-b]quinazoline (14-23, 26 and 27), and pyrido[4,3-d]thiazolo[3,2-a] pyrimidine (34-43, 45 and 46) analogues were designed and synthesized. The obtained compounds were evaluated for their in-vitro antitumor activity at the National Cancer Institute (NCI) 60 cell lines panel assay. Compounds 22, 38, 40 and 41 showed remarkable broad-spectrum antitumor activity. Compounds 22 and 38 are almost nine fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.5, >100, >100; and 2.4, 9.1, 36.2 mu M, respectively; while 40 and 41 are almost seven fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.9, 12.4, 46.6 and 3.0, 16.3, 54.0 mu M, respectively. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.023